The Summit Therapeutics study on PD1-VEGF antibody ivonescimab showcased promising results in delaying lung cancer progression among patients. This achievement aligns with prior findings and marks a significant milestone in Phase 3 clinical trials, highlighting advancements in cancer treatment. As the ASCO conference unfolds, these developments underscore the ongoing efforts to combat cancer globally, offering […]